synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
Company profile
Ticker
SNPX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEUROTROPE BIOSCIENCE, INC.
SEC CIK
Corporate docs
IRS number
461585656
SNPX stock data
Latest filings (excl ownership)
8-K
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
4 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
21 Dec 23
ARS
2022 FY
Annual report to shareholders
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
DEF 14A
Definitive proxy
13 Nov 23
8-K
Entry into a Material Definitive Agreement
6 Nov 23
PRE 14A
Preliminary proxy
3 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
Latest ownership filings
4
William S. Singer
10 Apr 24
4
Joshua Silverman
10 Apr 24
4
JONATHAN SCHECHTER
10 Apr 24
4
Bruce Bernstein
10 Apr 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
JONATHAN SCHECHTER
31 Mar 23
4
William S. Singer
31 Mar 23
4
Bruce Bernstein
31 Mar 23
4
Joshua Silverman
31 Mar 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.73 mm | 31.73 mm | 31.73 mm | 31.73 mm | 31.73 mm | 31.73 mm |
Cash burn (monthly) | 390.62 k | (no burn) | (no burn) | 46.68 k | 645.04 k | 296.66 k |
Cash used (since last report) | 2.61 mm | n/a | n/a | 312.07 k | 4.31 mm | 1.98 mm |
Cash remaining | 29.12 mm | n/a | n/a | 31.42 mm | 27.42 mm | 29.74 mm |
Runway (months of cash) | 74.5 | n/a | n/a | 673.0 | 42.5 | 100.3 |
Institutional ownership, Q3 2023
4.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 8 |
Closed positions | 1 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 114.86 mm |
Total shares | 1.10 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 786.71 k | $0.00 |
Geode Capital Management | 60.61 k | $26.67 mm |
Two Sigma Securities | 43.72 k | $19.24 mm |
Cannell Peter B & Co | 30.00 k | $13.20 mm |
Platform Technology Partners | 25.14 k | $11.06 mm |
Renaissance Technologies | 23.30 k | $10.00 k |
STT State Street | 20.10 k | $8.84 mm |
Millennium Management | 17.78 k | $7.82 mm |
Hayek Kallen Investment Management | 17.50 k | $8.00 k |
Vanguard | 17.39 k | $7.65 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Silverman Joshua | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 5.39 | 800 | 4.31 k | 800 |
8 Apr 24 | Schechter Jonathan | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 5.39 | 800 | 4.31 k | 800 |
8 Apr 24 | Singer William S. | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 5.39 | 800 | 4.31 k | 800 |
8 Apr 24 | Bernstein Bruce | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 5.39 | 800 | 4.31 k | 800 |
29 Mar 23 | Bernstein Bruce | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 0.87 | 20,000 | 17.40 k | 20,000 |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 Apr 24
Synaptogenix Acquires 25% Stake In Cannasoul
9 Apr 24
What's Going On With Synaptogenix (SNPX) Stock?
4 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
14 Mar 24
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
22 Feb 24